Treatment with Truvada (FOI)Treatment with Truvada (FOI)
Produced by the Freedom of Information officeAuthored by Government of Jersey and published on
13 December 2024.Prepared internally, no external costs.
Request
I am writing to make a formal request for information under the provisions of the Freedom of Information Act (FOIA). I am seeking answers to the following questions:
A
How many patients were treated in the last 6-month period with Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate for HIV treatment?
B
How many patients were treated in the last 6-month period with Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)?
C
How many packs of Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment?
D
How many packs of Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?
E
How many patients were treated in the last 6-month period with Descovy (tenofovir alafenamide / emtricitabine) for HIV treatment?
F
How many packs of Descovy (tenofovir alafenamide / emtricitabine) were dispensed in latest 6-month period for HIV treatment?
Response
Pharmacy records detail that Health and Community Services (HCS) have dispensed the following amounts of the specified medications in the last 6-month period:
A and B
68 unique patients were treated by HCS with Truvada or generic emtricitabine / tenofovir disoproxil fumarate in the last 6-month period.
C and D
214 packs of Truvada or generic emtricitabine / tenofovir disoproxil fumarate were dispensed to patients by HCS over the last 6-month period.
E
29 unique patients were treated by HCS with Descovy (tenofovir alafenamide / emtricitabine) in the last 6-month period.
F
142 packs of Descovy (tenofovir alafenamide / emtricitabine) were dispensed by HCS over the last 6-month period.
As noted in a Freedom of Information response published to www.gov.je in 2023, indication for treatment is not recorded within the Pharmacy dispensing system. Identifying this information would require cross-referencing of Pharmacy data for all prescriptions against records held under unique patient identifiers within the Sexual Health / Genitourinary Medicine and Blood-Borne Virus services, and manually interrogating each record. A Scheduled Public Authority is not required to create new datasets nor manipulate existing datasets in order to respond to Freedom of Information requests. Furthermore, the time necessary to identify and extract the data requested from the records that are available would exceed the timescales prescribed in the Freedom of Information (Costs) (Jersey) Regulations 2014. Therefore, Article 16 of the Freedom of Information (Jersey) Law 2011 has been applied.
Article applied
Article 16 - A scheduled public authority may refuse to supply information if cost excessive
(1) A scheduled public authority that has been requested to supply information may refuse to supply the information if it estimates that the cost of doing so would exceed an amount determined in the manner prescribed by Regulations.
gov.je